Vivos Therapeutics (VVOS) Profit After Tax (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Profit After Tax for 7 consecutive years, with -$7.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 98.74% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at -$25.1 million (down 122.69% YoY), while the FY2025 annual figure was -$21.2 million, down 90.37% from the prior year.
• Profit After Tax slipped to -$7.8 million in Q1 2026 per VVOS's latest filing, from -$6.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$1.7 million in Q1 2023 and bottomed at -$7.8 million in Q1 2026.
• Historically, Profit After Tax has averaged -$4.6 million across 5 years, with a median of -$5.0 million in 2025.
• Annual changes were most pronounced in 2023 — Profit After Tax soared 68.05% — and 2025, when it slumped 159.74%.
• Vivos Therapeutics' Profit After Tax stood at -$6.0 million in 2022, then advanced by 28.33% to -$4.3 million in 2023, then soared by 34.05% to -$2.8 million in 2024, then plunged by 144.15% to -$6.9 million in 2025, then slipped by 11.94% to -$7.8 million in 2026.
• Business Quant data shows VVOS's Profit After Tax at -$7.8 million in Q1 2026, -$6.9 million in Q4 2025, and -$5.4 million in Q3 2025.